28 May New! Vaxelis Contract Now Available
We are excited to announce that VAXELIS – developed in partnership between Sanofi Pasteur and Merck – is available to purchase through our Sanofi Pasteur agreement.
VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).
Effective June 1st, PAA members will have access to contract and prompt pay discounts on VAXELIS. Interested in Participating? Call us at 866-348-9780, or email Heather McKelton, PAA Account Development Manager, at HMcKelton@physall.com.
Not a member? Join now and access the many savings agreements PAA offers.
VAXELIS:
-
May help simplify the execution of the infant vaccination schedule with 2-3 fewer shots*
-
Is to be administered as a 3-dose series at 2, 4, and 6 months of age, with the first dose administered as early as 6 weeks of age
-
Comes in a ready-to-use formulation requiring no reconstitution and will be available in single-dose vials and prefilled syringes